Sickle cell disease patients with COVID‐19 in Guadeloupe: Surprisingly favorable outcomes
Emmanuelle Bernit,
Marc Romana,
Scylia Alexis‐Fardini,
Vanessa Tarer,
Pierre‐Marie Roger,
Lydia Doumdo,
Eléonore Petras,
Corine Charneau,
Benoit Tressières,
Marie Dominique Hardy Dessources,
Maryse Etienne‐Julan
Affiliations
Emmanuelle Bernit
Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
Marc Romana
Laboratoire d'Excellence du Globule Rouge (Labex GR‐Ex) PRES Sorbonne Paris France
Scylia Alexis‐Fardini
Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
Vanessa Tarer
Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
Pierre‐Marie Roger
Service d'infectiologie CHU de la Guadeloupe Pointe à Pitre Guadeloupe France
Lydia Doumdo
Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
Eléonore Petras
Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
Corine Charneau
Sickle Cell Disease Unit Centre Hospitalier de la Basse‐Terre Basse‐Terre France
Benoit Tressières
Centre d'Investigation Clinique Antilles Guyane Inserm CIC Point‐à‐Pitre Guadeloupe France
Marie Dominique Hardy Dessources
Laboratoire d'Excellence du Globule Rouge (Labex GR‐Ex) PRES Sorbonne Paris France
Maryse Etienne‐Julan
Sickle Cell Disease Unit Reference Centre for Sickle Cell Disease Thalassemia and Other Red Cell Rare Diseases CHU de la Guadeloupe Pointe‐à‐Pitre Guadeloupe France
Abstract We investigate risk factors for hospitalization and difference between sickle cell syndromes in a cohort of COVID‐19 sickle cell disease (SCD) adult patients managed in the Reference Center of Guadeloupe. We retrospectively collected data of symptomatic SCD adult patients infected with SARS‐CoV‐2 between March and December 2020. Thirty‐eight SCD adult patients with symptomatic COVID‐19 infection were included during the first wave, representing 9.6% of the active patient file at our center. The median age (IQR) was 39 years (24–47). Four patients were obese and two had moderate renal failure. The median duration of symptoms (IQR) was 10 days (5–15). Seventeen (44.7%) patients were hospitalized, including two in intensive care unit (ICU) for acute chest syndrome. An 85‐year‐old SC patient with prostate cancer died. No difference was detected between inpatient and outpatient groups in terms of age, gender, BMI, SCD clinical complications, and in history SCD treatment. There was no difference for severity, hospitalization, length of stay, ICU stay, or death between SS or Sβ°‐thal patients and SC or Sβ+‐thal patients. These overall favorable outcomes among symptomatic patients may be related to the low prevalence of comorbidity known to be linked to the more severe forms of COVID‐19, but also to the prompt coordinated management of SCD patients in the Reference Center.
